The NCCN risk grouping integrates multiple clinical variables—including PSA concentration, clinical tumor stage, Gleason GG and many detailed clinicopathological parameters—to produce a better tool of multifactorial risk assessment that reflects the true tumor’s biological behaviors alongside the disease burden [46]. Here, KLK3 is linked to neoplasm.